

Comparative Efficacy of Glucocorticoid Receptor Agonists on Th2 Cell Function and Attenuation by Progesterone

Alexander Luchak

Western University

Lauren A Solomon

Western University

Tharsan Kanagalingam

Western University

Meerah Vijeyakumaran

Western University

Brian H Rowe

University of Alberta

Lisa Cameron (✉ Lisa.Cameron@schulich.uwo.ca)

<https://orcid.org/0000-0002-2108-8414>

Research article

Keywords: asthma, Th2 cells, type 2 cytokine, IL-13, apoptosis, corticosteroid, sex hormone, progesterone

Posted Date: August 14th, 2020

DOI: <https://doi.org/10.21203/rs.2.14497/v3>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published on October 19th, 2020. See the published version at <https://doi.org/10.1186/s12865-020-00383-8>.

Abstract

Background: Corticosteroids (CS)s suppress cytokine production and induce apoptosis of inflammatory cells. Prednisone and dexamethasone are oral CSs prescribed for treating asthma exacerbations. While prednisone is more commonly prescribed, dexamethasone is long acting and a more potent glucocorticoid receptor (GR) agonist. It can be administered as a one or two dose regime, unlike the five to seven days required for prednisone, a feature that increases compliance. We compared the relative ability of these two oral CSs to suppress type 2 inflammation. Since progesterone has affinity for the GR and women are more likely to relapse following an asthma exacerbation, we assessed its influence on CS action.

Results: Dexamethasone suppressed the level of IL-5 and IL-13 mRNA within Th2 cells with ~10-fold higher potency than prednisolone (the active form of prednisone). Dexamethasone induced a higher proportion of apoptotic and dying cells than prednisolone, at all concentrations examined. Addition of progesterone reduced the capacity of both CS to drive cell death, though dexamethasone maintained significantly more killing activity. Progesterone blunted dexamethasone-induction of FKBP5 mRNA, indicating that the mechanism of action was by interference of the GC:GR complex.

Conclusions: Dexamethasone is both more potent and effective than prednisolone in suppressing type 2 cytokine levels and mediating apoptosis. Progesterone attenuated these anti-inflammatory effects, indicating its potential influence on CS responses *in vivo*. Collectively, our data suggest that when oral CS is required, dexamethasone may be better able to control type 2 inflammation, eliminate Th2 cells and ultimately lead to improved long-term outcomes. Further research in asthmatics is needed.

Background

Allergic asthma is typified by allergen-induced differentiation of T helper 2 (Th2) cells and their production of the type 2 cytokines IL-4, IL-5, and IL-13 [1]. Together these cytokines orchestrate much of the pathophysiology of asthma: IL-4 and IL-13 regulate B cell isotype switching to IgE [2] and upregulate endothelial expression of VCAM-1, mediating eosinophil infiltration [3]. IL-5 directs eosinophil differentiation and survival [4, 5] and IL-13 drives mucus production [6] and airway fibrosis [7-9]. More recently, group 2 innate lymphoid cells (ILC2) have also been shown to produce type 2 cytokines [10], though they are activated by TSLP, IL-33 or IL-25 released from the epithelium following exposure not only to allergens but also various microbes [11].

Corticosteroids (CS)s are an effective treatment for most asthmatics [12] due in part to their ability to suppress type 2 cytokine expression, both *in vitro* and *in vivo* [13-17]. While CSs also induce apoptosis of eosinophils [18] and peripheral blood mononuclear cells [19], within the T lymphocyte population there are differences in sensitivity to CSs across the various subsets. For instance, Brinkmann *et. al.* showed that memory T cells were 100-fold less sensitive to steroid-mediated reduction in clonal expansion than naïve T cells [20]. While Banuelos *et. al.* observed that Th1 cells seem more sensitive to steroid-induced

apoptosis than Th17 cells [21], the susceptibility of human Th2 cells has not been well studied. Since the persistence of symptoms in difficult-to-treat asthma is largely attributed to the presence and repeated activation of long-lived memory Th2 cells and subsequent inflammation [22, 23], therapies aimed at their elimination have the potential to mediate lasting effects.

In asthma, the need for systemic (e.g., oral, intravenous or intramuscular) CS agents arise when inhaled CSs (ICS) fail to control symptoms or allergen/irritant exposure stimulates the inflammatory response and leads to an asthma exacerbation. In severe asthma, patients can be dependent on oral CS agents with symptoms worsening upon withdrawal [12, 24]. Due to well-known and serious systemic side effects [25], however, long term use of oral CS is not advised and guidelines now recommend prioritizing anti-Th2 therapies for asthma control [12, 24]. Oral CS is recommended for acute conditions, such as exacerbations of asthma, and has been shown to significantly reduce the risk of hospitalization and relapse following discharge [26]. In adults, prednisone is the most commonly prescribed oral CS [27] though an alternative is dexamethasone, a more potent agonist for the glucocorticoid receptor (GR) [27, 28]. A number of studies have compared short burst oral prednisone and dexamethasone in treating exacerbations of asthma and shown they have similar safety profiles, especially in children [29-35]. Their relative ability to suppress type 2 inflammation, however, has not been closely examined.

Here, we performed a head-to-head comparison of the relative anti-inflammatory capacity of prednisolone (the active form of prednisone) and dexamethasone *in vitro*. Sex as a biological variable is an important consideration in asthma. Women are more likely than men to develop severe asthma [36] and to relapse after an asthma attack [37]. Fluctuations in female sex hormones during the menstrual cycle [38] and pregnancy [39] are associated with worsening of asthma symptoms [40]. Since progesterone has affinity for the GR [41], this hormone may influence how CSs influence type 2 immunity. As such, we also examined the ability of progesterone to interfere with the action of prednisolone and dexamethasone. Collectively, our study provides insight into the relative efficacy of these two CS therapies and suggests their effects may be dampened in women.

Results

Dexamethasone more potently reduces type 2 cytokine levels than prednisolone

To directly compare the ability of dexamethasone and prednisolone to suppress type 2 cytokine production, primary Th2 cells (Supplemental Figure 1 (Figure S1)) [42, 43] cultured in IL-2 (4 days) were treated (24 hours) with equimolar concentrations of either CS (10^{-9} - 10^{-7} M) as in [15, 18]. Moreover, these concentrations are within the pharmacological range [44]. IL-13 mRNA was decreased following treatment with all concentrations of dexamethasone (Figure 1A). A 10-fold higher concentration of prednisolone was needed to significantly reduce IL-13, as the level of this cytokine was only lower in cells that had been cultured with concentrations of prednisolone $\geq 10^{-8}$ M (Figure 1A). The half maximal inhibitory concentration (IC_{50}) of dexamethasone to suppress IL-13 mRNA was significantly lower than prednisolone (Figure 1B), though these two CSs showed similar maximal efficacy (Figure 1C). IL-5 mRNA

level was also inhibited by both CSs, though dexamethasone was effective at a 10-fold lower concentration than prednisolone (Figure 1D). There was no significant difference in the potency (Figure 1E) or efficacy (Figure 1F) of either CS to suppress IL-5 mRNA. In a broader analysis of Th2 cell response to dexamethasone we performed RNA sequencing and found that not all cytokines were suppressed; some were unchanged, some were increased and IFN γ was reduced, indicating no redirection to a Th1 phenotype (Table 1). There were also no differences in cell counts over this 24 hour period, indicating that the reduction in level of cytokine mRNA was not due to cell death (Figure 1G). These results show that dexamethasone is more potent than prednisolone in suppressing the level of type 2 cytokines.

Dexamethasone has a higher maximal efficacy than prednisolone to induce apoptosis

To assess the efficacy of dexamethasone and prednisolone to induce apoptotic cell death we used a CD4⁺ T lymphoblastoid cell line (CCRF-CEM). This line exhibits a Th2 phenotype, with enriched expression of the Th2 markers GATA3 and CRTh2 compared to Jurkat T cells (Figure Supplemental 2 (Figure S2)). Flow cytometry was used to quantify Annexin V and 7-AAD staining following 48 hours of CS treatment. Early apoptotic cells were identified as those staining for Annexin V only, but not 7-AAD, and cells positive for 7-AAD alone were considered necrotic (Figure S3). We recently reported similar responses to dexamethasone-induced apoptosis when comparing the CCRF-CEM cell line to primary Th2 cells [45]. When we examined the response to prednisolone and dexamethasone we found that both CSs induce necrosis of CCRF-CEM cells in a dose dependent manner (Figure 2A). Dexamethasone had a half maximal response (EC₅₀) significantly lower than prednisolone (Figure 2B) and was also the more effective inducer of cell death (Figure 2C). Similarly, both CSs induced apoptosis (Figure 2D), though dexamethasone was more potent (Figure 2E) and more effective (Figure 2F) than prednisolone. Figure 2G shows the response of primary Th2 cells to dexamethasone-induced apoptosis was similar to CCRF-CEM, reaching a plateau at 0.5 mM.

Progesterone antagonizes corticosteroid-induced apoptosis

Since progesterone has affinity for the GR [41], we investigated whether this sex hormone influences the efficacy of CS action. Th2 cells (CCRF-CEM) were incubated with dexamethasone for 48 hours in the presence or absence of progesterone and cell death and apoptosis assessed by flow cytometry. We found that progesterone, in the absence of dexamethasone, had no effect but when added with or 30 minutes prior to dexamethasone significantly reduced both cell death (Figure 3A) and apoptosis (Figure 3B). To assess the differential effect of progesterone on either CS, Th2 cells were cultured with prednisolone or dexamethasone in the presence or absence of progesterone. Head-to-head comparison revealed that the proportion of apoptotic cells induced by prednisolone (Figure 3C) and dexamethasone (Figure 3D) was reduced by progesterone, though no significant change in EC₅₀ for either CS was observed (Figure 3E). Progesterone did reduce the maximal efficacy of both CSs (Figure 3F), though dexamethasone maintained superior killing activity over prednisolone at each progesterone concentration (Figure 3G).

Progesterone inhibits GR signaling

To investigate the mechanism by which progesterone reduced the CS effect, we examined expression of the nuclear progesterone receptor (*PGR*). We found that in the Th2 cell line (CCRF-CEM) and primary Th2 cells *PGR* mRNA was undetectable by qRT-PCR, though present in a breast cancer cell line (MCF-7) (Figure 4A). We also found no induction of progesterone immunomodulatory binding factor 1 (PIBF1), a factor known to be induced by progesterone [46, 47] (Figure 4B), in CCRF-CEM nor primary Th2 cells treated with dexamethasone (Table 1). These results suggest that the progesterone effect on CS-induced apoptosis was not through progesterone receptor signaling. Since progesterone has also been shown to have affinity for the GR [41], we next assessed whether it could influence the dexamethasone mediated induction of FKBP5 mRNA, a gene highly induced by CS [45, 48, 49]. Indeed, the level of FKBP5 mRNA following exposure to dexamethasone was significantly blunted when progesterone was added to the culture (Figure 4C), indicating this sex hormone interferes with GC:GR signaling.

Discussion

Prednisone and dexamethasone are both oral CS therapies recommended for treating patients with moderate to severe asthma exacerbations. While prednisone is more commonly used [27], studies in children and adults have shown that dexamethasone has a similar safety profile and efficacy in terms of reducing relapse rates, hospitalizations, symptoms and time to return to normal activity [29, 30, 33-35]. Moreover, its long half-life and shorter treatment duration have proven popular among patients, caregivers and clinicians, especially in children with acute asthma. Dexamethasone is a more potent GR agonist than prednisone [28]; however, whether it is more effective in reducing inflammation is less well understood. Here, we examined the anti-inflammatory effects of these two CS agents *in vitro* and found that dexamethasone was both more potent and more effective than prednisolone. As such, our data suggest that treating exacerbating asthmatics with dexamethasone may result in better control of symptoms and/or severity of disease, aspects of asthma mediated by persistent inflammation.

Studies comparing the effectiveness of standard dose regimes of dexamethasone (12-16 mg/day, 1-2 days) to prednisone (60 mg/day, 5 days) found no difference in asthma relapse rates within two weeks [33-35]. These studies, however, failed to examine longer time points or differential CS effects on cellular or cytokine responses. Our study shows that dexamethasone significantly decreased IL-13 mRNA at a 10-fold lower concentration (10^{-9} mM) than prednisolone. IL-5 appeared to be generally less CS sensitive, with significant suppression observed only at 10^{-8} mM dexamethasone. However, at the highest concentration examined (10^{-7} μ M), still physiologically relevant [44], both CS agents almost completely suppressed IL-13 and IL-5 mRNA levels. This result indicates that *in vivo* type 2 cytokines are likely sufficiently controlled with an optimal dose of either prednisolone or dexamethasone and, in line with other reports, are anticipated to reduce the proportion of CD4⁺ T cells expressing IL-4 and IL-5 [50]. However, we recently showed that the suppressive effect of dexamethasone on IL-13 was reversed after activation unless cells were continuously exposed to dexamethasone [45], suggesting the effect could be temporary. The lack of increase in IL-10 or IL-17 following dexamethasone treatment [45], coupled with our new data showing that dexamethasone reduced IFN γ mRNA levels (Table 1), indicates active

suppression of type 2 cytokine transcription, rather than shifting Th2 cells toward a Th1, Th17 or T regulatory cell phenotype.

Type 2 cytokines mediate many features of asthma and therapies blocking their action are effective and are now recommended as frontline controllers in severe asthma [24]. Attention, however, is now turning toward therapies that reduce the proportion and/or development of type 2 cytokine-producing cells with the long term hope of actually modifying or curing asthma [51]. Circulating Th2 cells are an important aspect of immune memory and their level controls a patient's susceptibility to respond to allergens and the development of persistent symptoms. For this reason, we examined differences in the ability of these two CS agents to induce Th2 cell apoptosis. We found that dexamethasone was superior to prednisolone in driving apoptosis (~10-fold more effective) - no matter the concentration added, prednisolone was never able to induce apoptosis to a similar degree as dexamethasone. These results suggest prednisolone is a partial agonist, relative to dexamethasone, similar to previous studies showing this in terms of gene expression [52] and the ability of dexamethasone to enhance prednisolone-induced cytotoxicity [53].

Prednisolone failed to match the degree of dexamethasone-induced apoptosis, but was equi-effective in cytokine suppression. This difference may be due to mechanism(s) of action. Corticosteroid suppression of IL-5 and IL-13 has been shown to be due to GR interfering with transcription factors binding to the promoter of these type 2 cytokine genes [14], while GC-induced apoptosis has been associated with induction of pro-apoptotic genes such as BIM (BCL-2-interacting mediator of cell death) [54]. Our results suggest that dexamethasone more effectively induces pro-apoptosis genes than prednisolone. Indeed, others have shown differential effects of various steroids on gene expression; in airway cells dexamethasone, fluticasone, ciclesonide (and others) were equally effective in driving the expression of some genes (GILZ, p57^{kip2}), but not others (PDK4) [55].

Clearly, studies are needed to examine the effect of dexamethasone compared to prednisone in patients experiencing asthma exacerbation, but this is challenging since dexamethasone is more often prescribed to children and prednisolone is the oral CS of choice in adults. A few studies have compared these two CSs and found they were associated with similar rates of relapse and hospitalization within 10-14 days [34, 35], providing little rationale to recommend a change in prescribing habits. Those studies, however, did not assess whether dexamethasone had a stronger suppressive effect on immune cell responses such as the degree of Th2 cell apoptosis. There is evidence to suggest that stronger GR agonists provide better outcomes; Demirca *et. al.* showed type 2 cytokine expression at day 7 following *ex vivo* activation of peripheral blood mononuclear cells was higher in patients who received oral methylprednisolone post-exacerbation compared to those who received the more potent fluticasone propionate [56]. Our mechanistic data suggest that the higher potency dexamethasone induced more Th2 cell apoptosis than the weaker agonist prednisone. *In vivo*, dexamethasone may be better able to eliminate Th2 cells thereby reducing persistent symptoms driven by type 2 inflammation and could result in fewer sub-acute relapses and/or repeat exacerbations. As such, our *in vitro* data beseech clinical centers to perform head-to-head

comparisons of these two CS agents to determine their relative *in vivo* effect on type 2 inflammation and persistence of symptoms.

Since corticosteroid withdrawal studies have shown that suppression of type 2 inflammation requires continuous exposure to steroid [45, 57, 58], therapeutic approaches aimed at eliminating Th2 cells may provide more sustained repression of allergic responses. Th2 cells are highly differentiated with a strong ability to survive, mediated through expression of the anti-apoptotic factor BCL-2 [59, 60]. The BCL-2 inhibitor ABT-199, in clinical trials for leukemia [61], was also shown to reduce the level of airway eosinophils and Th2 cells in a mouse model of asthma [62]. Huang *et. al.* showed that elimination of Th2 cells (using an antibody against CRTh2) resulted in significantly fewer eosinophils and lower levels of type 2 cytokines and chemokines in the blood, lymph nodes and lung in a mouse model of asthma [63]. Ultimately, therapies targeting development of Th2 cells, such as those blocking the IL-4Ra or the cytokine TSLP [64, 65], may prove the most effective in reducing persistence of asthma symptoms.

Women and men respond differently to acute asthma. For example, women are more likely to relapse following an asthma exacerbation than men [37]. Furthermore, the female sex hormone progesterone has affinity for the GR [41]. As such, we examined whether progesterone could dampen the ability of CS to induce Th2 cell apoptosis and its mechanism of action. We found that progesterone (1mM, considered to be a physiologic level during pregnancy [41]), interfered with both prednisolone and dexamethasone and that the effect was identical if hormone was added in combination or as a pre-treatment. The Th2 cell line (CCRF-CEM) and primary Th2 cells had no PGR mRNA and no production of PIBF1 mRNA in response to progesterone, indicating that the effect was not due to activation of nuclear progesterone receptors [46]. We did, however, find that progesterone reduced the level of FKBP5 mRNA, a gene known to be induced by GC exposure and GR binding to its promoter [48, 49]. As such, our data suggest that progesterone antagonizes GC:GR signaling, rather than acting through its own receptor. This finding is in line with Guo *et. al.*, who showed that treating murine NK cells with the progesterone analog P4, in the presence of PGR blockade, antagonized GR signaling and reduced IFN γ and CD69 expression following CpG/IL-12 stimulation [66]. Progesterone was also shown to antagonize dexamethasone-induced apoptosis of murine thymocytes [67]. Collectively these studies support our hypothesis that circulating progesterone levels may influence the efficacy of CS action *in vivo*, which could explain why some women experience worse symptoms at times when progesterone levels are elevated [38, 39] and are more likely to be diagnosed with severe asthma [36].

Dexamethasone is a long-acting CS (36-72 hour half-life) with 30 times more GR activity than hydrocortisone. Due to these factors, long term dexamethasone treatment is associated with serious side effects, such as suppression of the hypothalamic-pituitary-adrenal (HPA) axis, so is generally reserved for treating acute symptoms like exacerbations of asthma [27]. Prednisolone is less potent (4 times the activity of hydrocortisone) and is shorter acting (12-36 hour half-life) [27], so historically it has been used as a controller medication. In 2012, due to the known side effects of long term oral steroid use, the GINA guidelines downgraded the use of oral CS in chronic asthma and recommend them only if other controllers, such as anti-IgE and anti-IL-5, were not available or did not work [68]. Nevertheless, a recent

study of severe asthmatics reported a third of their study population was using oral prednisone, with an average duration of 4 years and mean dose 17.5 mg/day [69]. The ranges of oral prednisone prescribed vary greatly from very low (1 - 7.5 mg/day) to higher doses (10 - 40 mg/day) [68]. Though less than recommended for exacerbation (60 mg/day) [34, 35], these doses equate to *in vitro* concentrations of ~ 0.3 - 0.8 mM (7.5 - 17.5 mg/day). In light of our data, the dose range of prednisolone for chronic use may be sufficient to suppress type 2 cytokine levels, but relatively inefficient as an inducer of apoptosis, particularly in women. These data indicate that inhaled CS formulations of higher affinity GR agonists, such as fluticasone furoate [70], may also be effective in eliminating Th2 cells and suggest this should be examined in future studies.

In conclusion, our study provides an *in vitro* examination of the anti-inflammatory capacity of two clinically relevant corticosteroids, prednisolone and dexamethasone. We found that dexamethasone more potently and effectively reduced type 2 cytokine expression and diminished Th2 cell numbers than prednisolone. In the presence of progesterone, dexamethasone maintained a superior ability to drive Th2 cell death over prednisolone. Though further study is needed to assess these effects in patients with asthma, our results do suggest that amongst oral CSs dexamethasone may be the better therapeutic option for treating exacerbations of asthma, particularly in women.

Materials And Methods

This study was approved by the Western University Health Sciences Research Ethics Board (Approval number 106770). All subjects gave informed consent.

Th2 cells

Primary Th2 cells were differentiated from CD4⁺ T cells obtained from healthy donor peripheral blood mononuclear cells (PBMCs) and cultured under Th2 differentiating conditions as previously described [43]. Th2 cells were maintained on cycles of IL-2 and plate bound α CD3/ α CD28 (3 days) or just IL-2 (4 days) at 2×10^6 cells/mL. The immortalized cell lines CCRF-CEM (ATCC® CCL-119™) and Jurkat (ATCC® E6-1, TIB-152™) were purchased from American Type Culture Collection (VA). They are both CD4⁺ T cell lines derived from acute human T cell leukemia. Cell lines were grown in RPMI-1640 media (Sigma-Aldrich) supplemented with 10% FBS (Hyclone Scientific, Fisher Scientific, ON, Canada) and 1X penicillin-streptomycin-glutamine (Gibco, Invitrogen, Thermo Fisher Scientific). Cells were incubated at 37°C, in 85% humidity and 5% CO₂ and maintained at $0.2 - 0.3 \times 10^6$ cells/mL with re-seeding every 2 days.

Cell Culture Conditions

Dexamethasone, prednisolone and progesterone (Sigma Aldrich, ON, Canada) were prepared in 100% ethanol and serially diluted in culture medium prior to treatment of primary Th2 cells (1.3×10^6 cells/mL) and CCRF-CEM cells (0.2×10^6 cells/mL). While prednisone is most commonly prescribed to patients, it needs to be metabolized in the liver to prednisolone, the active drug. Therefore, we used prednisolone for

these *in vitro* experiments. Cells were treated with 10^{-9} – 10^{-7} mM of each CS agent as in [15, 18]. These concentrations were based on the relative anti-inflammatory activity of dexamethasone being 6.25-fold more potent than prednisolone (<https://clincalc.com>). Moreover, they are within the pharmacological range - oral administration of dexamethasone (12 mg, $\sim 0.26 \mu\text{M}$) and prednisone (60 mg, $\sim 2.76 \mu\text{M}$) [44]. For experiments with progesterone, cells were either incubated with progesterone for 30 minutes prior to dexamethasone or added simultaneously with dexamethasone. Gene expression was assessed after 24 hours and staining for flow cytometry conducted after 48 hours.

Gene Expression

Quantitative RT-PCR RNA (400ng) was isolated with RNeasy Plus Mini/QIAshredder (Qiagen, Hilden, Germany) and reverse transcribed using iScript Reverse Transcription Supermix (Bio-Rad, Hercules, California). Real time polymerase chain reaction (RT-PCR) was conducted using TaqMan Fast Advanced Master Mix (Applied Biosystems, Foster City, California). Assays for IL-13 (Hs00174379_m1), IL-5 (Hs01548712_g1), PGR (Hs01556702_m1), PIBF1 (Hs00197131_m1), FKBP5 (Hs01561006_m1), CRTh2 (Hs00173717_m1), GATA3 (Hs00231122_m1), IFN γ (Hs00989291_m1) and the housekeeping gene GAPDH (Hs02786624_g1) were used (ThermoFisher). Thermal cycling was according to manufacturer's instruction. Fold increase relative to the control condition was assessed for experimental treatments using the $2^{-\Delta\Delta CT}$ method.

RNA-sequencing Messenger RNA (mRNA) sequencing was previously conducted on primary Th2 cells treated for 24 hours in vehicle or 0.1 mM dexamethasone as described [45]. Normalized expression counts are presented from samples treated with ethanol (vehicle) or dexamethasone at 0.1 μM for 24 hours.

Flow Cytometry

Cytokine expression Intracellular staining to characterize primary Th2 cells was previously described in [42, 43]. Briefly, cytokine staining for IL-4, IL-13 and IFN γ was performed following 4 hours of stimulation with PMA (20ng/mL) and ionomycin (1 μM) in the presence of Brefeldin A (10 $\mu\text{g}/\text{mL}$, all from Sigma Aldrich, Canada). Cells were fixed on ice (10 min) with paraformaldehyde (4%; Sigma Aldrich, Canada) and permeabilized on ice (10 min) with saponin (0.4%, Sigma Aldrich, Canada). Cells were incubated with at 4°C (30 min) with IL-13-PE (Clone JES10-5A2, isotype rat IgG1 κ PE), IFN γ -Alexa 647 (Clone B27, isotype mouse IgG1 κ Alexa 647) or IL-4-Alexa 488 (Clone 8D4-8, isotype mouse IgG1 κ Alexa 488) antibodies (BD Pharmingen, ON, Canada) and then washed with buffer. Fluorescence was assessed immediately using a FACS Calibur (Becton Dickson, ON, Canada) and data analyzed using FlowJo (Tree Star Inc, Ashland, OR, USA).

Apoptosis Following 48 hours CS treatment, CCRF-CEM or primary Th2 cells (0.5×10^6 cells/ml) were washed with FACS buffer (0.5% bovine serum albumin, 0.1% sodium azide, 3% FBS), pelleted at 4°C, re-suspended in Annexin V binding buffer (100 $\mu\text{L}/\text{condition}$; 10mM HEPES pH 7.4, 140mM NaCl, 2.5mM CaCl $_2$) and stained with Alexa Fluor 647 Annexin V (1 μL) and 7-AAD Viability Staining Solution (5 μL)

(BioLegend, CA, USA) for 15 minutes. Cells were diluted with additional Annexin V binding buffer (400µL) and data acquired using an LSR II (BD Biosciences). Flow cytometry analysis was conducted using FlowJo (Version 10, Ashland, OR, USA) and reported as the proportion of total cell population.

Statistical Analysis

Two- and one-way repeated measures analysis of variance (ANOVA) were used to determine statistical significance at $p < 0.05$ (SigmaPlot, version 12.5).

Declarations

- **Ethics approval and consent to participate:** Informed consent to participate in the study was obtained from all participants.
- **Consent for publication:** Not applicable
- **Availability of data and material:** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
- **Competing interests:** The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
- **Funding:** Operating grants from the Canadian Institute of Health Research (CIHR), Grant-in-Aid from AllerGen/Canadian Allergy, Asthma and Immunology Foundation, bridge funding from Western University and summer student funding from the Schulich School of Medicine and Dentistry's Dean's Undergraduate Research Opportunities Program (DUROP).
- **Authors' contributions:** AL conducted cell culture and apoptosis experiments with CCRF-CEM cells and flow cytometry staining. LAS conducted culture of primary Th2 cells, collected and analyzed all flow cytometry data and prepared the manuscript. TK established staining protocols, drug dosing and assisted with flow cytometry. MV contributed apoptosis data from Th2 cells. BHR highlighted the need for this investigation and contributed clinical insight for the study design, data interpretation and manuscript revision. LC conceived of the study, oversaw all experiments and wrote the final manuscript.
- **Acknowledgements** The authors wish to acknowledge Liliane Cabral-Fernandes who assisted with quantifying cytokine gene expression. Dr. B.H. Rowe is supported by CIHR as the Scientific Director of the Institute of Circulatory and Respiratory Health (ICRH) in Ottawa, ON.

References

1. Zhu J: **T helper 2 (Th2) cell differentiation, type 2 innate lymphoid cell (ILC2) development and regulation of interleukin-4 (IL-4) and IL-13 production.** *Cytokine* 2015, **75**(1):14-24.
2. Punnonen J, Aversa G, Cocks BG, McKenzie AN, Menon S, Zurawski G, de Waal Malefyt R, de Vries JE: **Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells.** *Proc Natl Acad Sci U S A* 1993, **90**(8):3730-3734.

3. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP: **IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells.** *J Immunol* 1995, **154**(2):799-803.
4. Clutterbuck EJ, Hirst EM, Sanderson CJ: **Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: comparison and interaction with IL-1, IL-3, IL-6, and GM-CSF.** *Blood* 1989, **73**(6):1504-1512.
5. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, Suzuki J, Isobe M, Sekiguchi M: **Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis.** *Intern Med* 1997, **36**(3):179-185.
6. Kondo M, Tamaoki J, Takeyama K, Isono K, Kawatani K, Izumo T, Nagai A: **Elimination of IL-13 reverses established goblet cell metaplasia into ciliated epithelia in airway epithelial cell culture.** *Allergol Int* 2006, **55**(3):329-336.
7. Corren J: **Role of interleukin-13 in asthma.** *Curr Allergy Asthma Rep* 2013, **13**(5):415-420.
8. Humbert M, Menz G, Ying S, Corrigan CJ, Robinson DS, Durham SR, Kay AB: **The immunopathology of extrinsic (atopic) and intrinsic (non-atopic) asthma: more similarities than differences.** *Immunol Today* 1999, **20**(11):528-533.
9. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA: **Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production.** *J Clin Invest* 1999, **103**(6):779-788.
10. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Druenen CM, Piet B, Fokkens WJ, Cupedo T, Spits H: **Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CCR2 and CD161.** *Nat Immunol* 2011, **12**(11):1055-1062.
11. Divekar R, Kita H: **Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation.** *Curr Opin Allergy Clin Immunol* 2015, **15**(1):98-103.
12. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, Adcock IM, Bateman ED, Bel EH, Bleecker ER *et al.*: **International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.** *European Respiratory Journal* 2014, **43**(2):343.
13. Braun CM, Huang SK, Bashian GG, Kagey-Sobotka A, Lichtenstein LM, Essayan DM: **Corticosteroid modulation of human, antigen-specific Th1 and Th2 responses.** *J Allergy Clin Immunol* 1997, **100**(3):400-407.
14. Jee YK, Gilmour J, Kelly A, Bowen H, Richards D, Soh C, Smith P, Hawrylowicz C, Cousins D, Lee T *et al.*: **Repression of interleukin-5 transcription by the glucocorticoid receptor targets GATA3 signaling and involves histone deacetylase recruitment.** *J Biol Chem* 2005, **280**(24):23243-23250.
15. Kaur M, Reynolds S, Smyth LJ, Simpson K, Hall S, Singh D: **The effects of corticosteroids on cytokine production from asthma lung lymphocytes.** *Int Immunopharmacol* 2014, **23**(2):581-584.
16. Schwiebert LM, Beck LA, Stellato C, Bickel CA, Bochner BS, Schleimer RP, Schwiebert LA: **Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions.** *J Allergy Clin Immunol* 1996, **97**(1 Pt 2):143-152.

17. Naseer T, Minshall EM, Leung DY, Laberge S, Ernst P, Martin RJ, Hamid Q: **Expression of IL-12 and IL-13 mRNA in asthma and their modulation in response to steroid therapy.** *Am J Respir Crit Care Med* 1997, **155**(3):845-851.
18. Zhang X, Moilanen E, Kankaanranta H: **Enhancement of human eosinophil apoptosis by fluticasone propionate, budesonide, and beclomethasone.** *Eur J Pharmacol* 2000, **406**(3):325-332.
19. Melis M, Siena L, Pace E, Gjomarkaj M, Profita M, Pirazzoli A, Todaro M, Stassi G, Bonsignore G, Vignola AM: **Fluticasone induces apoptosis in peripheral T-lymphocytes: a comparison between asthmatic and normal subjects.** *Eur Respir J* 2002, **19**(2):257-266.
20. Brinkmann V, Kristofic C: **Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO- and CD45RO+ subsets.** *J Immunol* 1995, **155**(7):3322-3328.
21. Banuelos J, Shin S, Cao Y, Bochner BS, Morales-Nebreda L, Budinger GR, Zhou L, Li S, Xin J, Lingen MW *et al*: **BCL-2 protects human and mouse Th17 cells from glucocorticoid-induced apoptosis.** *Allergy* 2016, **71**(5):640-650.
22. Mojtabavi N, Dekan G, Stingl G, Epstein MM: **Long-lived Th2 memory in experimental allergic asthma.** *J Immunol* 2002, **169**(9):4788-4796.
23. Woodland DL, Kohlmeier JE: **Migration, maintenance and recall of memory T cells in peripheral tissues.** *Nature reviews Immunology* 2009, **9**(3):153-161.
24. (GINA) GfA: **Difficult-to-Treat and Severe Asthma in Adolescents and Adult Patients Pocket Guide.** In: <https://ginasthma.org/>. 2019.
25. Fardet L, Kassir A, Cabane J, Flahault A: **Corticosteroid-induced adverse events in adults: frequency, screening and prevention.** *Drug Saf* 2007, **30**(10):861-881.
26. Rowe BH, Spooner CH, Ducharme FM, Bretzlaff JA, Bota GW: **Corticosteroids for preventing relapse following acute exacerbations of asthma.** *Cochrane Database Syst Rev* 2007(3):CD000195.
27. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, Brown JP, Cohen A, Kim H: **A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy.** *Allergy Asthma Clin Immunol* 2013, **9**(1):30.
28. Daley-Yates PT: **Inhaled corticosteroids: potency, dose equivalence and therapeutic index.** *Br J Clin Pharmacol* 2015, **80**(3):372-380.
29. Shefrin AE, Goldman RD: **Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients.** *Can Fam Physician* 2009, **55**(7):704-706.
30. Altamimi S, Robertson G, Jastaniah W, Davey A, Dehghani N, Chen R, Leung K, Colbourne M: **Single-dose oral dexamethasone in the emergency management of children with exacerbations of mild to moderate asthma.** *Pediatr Emerg Care* 2006, **22**(12):786-793.
31. Greenberg RA, Kerby G, Roosevelt GE: **A comparison of oral dexamethasone with oral prednisone in pediatric asthma exacerbations treated in the emergency department.** *Clin Pediatr (Phila)* 2008, **47**(8):817-823.

32. Hendeles L: **Selecting a systemic corticosteroid for acute asthma in young children.** *J Pediatr* 2003, **142**(2 Suppl):S40-44.
33. Kravitz J, Dominici P, Ufberg J, Fisher J, Giraldo P: **Two days of dexamethasone versus 5 days of prednisone in the treatment of acute asthma: a randomized controlled trial.** *Ann Emerg Med* 2011, **58**(2):200-204.
34. Qureshi F, Zaritsky A, Poirier MP: **Comparative efficacy of oral dexamethasone versus oral prednisone in acute pediatric asthma.** *J Pediatr* 2001, **139**(1):20-26.
35. Rehrer MW, Liu B, Rodriguez M, Lam J, Alter HJ: **A Randomized Controlled Noninferiority Trial of Single Dose of Oral Dexamethasone Versus 5 Days of Oral Prednisone in Acute Adult Asthma.** *Ann Emerg Med* 2016, **68**(5):608-613.
36. **The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Network for Understanding Mechanisms of Severe Asthma.** *Eur Respir J* 2003, **22**(3):470-477.
37. Rowe BH, Villa-Roel C, Sivilotti ML, Lang E, Borgundvaag B, Worster A, Walker A, Ross S: **Relapse after emergency department discharge for acute asthma.** *Acad Emerg Med* 2008, **15**(8):709-717.
38. Vrieze A, Postma DS, Kerstjens HA: **Perimenstrual asthma: a syndrome without known cause or cure.** *J Allergy Clin Immunol* 2003, **112**(2):271-282.
39. Malassine A, Frenco JL, Evain-Brion D: **A comparison of placental development and endocrine functions between the human and mouse model.** *Hum Reprod Update* 2003, **9**(6):531-539.
40. Murphy VE, Gibson PG, Smith R, Clifton VL: **Asthma during pregnancy: mechanisms and treatment implications.** *Eur Respir J* 2005, **25**(4):731-750.
41. Engler JB, Kursawe N, Solano ME, Patas K, Wehrmann S, Heckmann N, Lühder F, Reichardt HM, Arck PC, Gold SM *et al*: **Glucocorticoid receptor in T cells mediates protection from autoimmunity in pregnancy.** *Proc Natl Acad Sci U S A* 2017, **114**(2):E181-E190.
42. Bredo G, Storie J, Shrestha Palikhe N, Davidson C, Adams A, Vliagoftis H, Cameron L: **Interleukin-25 initiates Th2 differentiation of human CD4(+) T cells and influences expression of its own receptor.** *Immunity, Inflammation and Disease* 2015, **3**(4):455-468.
43. MacLean Scott E, Solomon LA, Davidson C, Storie J, Palikhe NS, Cameron L: **Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism.** *PLoS One* 2018, **13**(7):e0199156.
44. Czock D, Keller F, Rasche FM, Häussler U: **Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.** *Clin Pharmacokinet* 2005, **44**(1):61-98.
45. Kanagalingam T, Solomon L, Vijeyakumaran M, Palikhe NS, Vliagoftis H, Cameron L: **IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation?** *Immun Inflamm Dis* 2019.
46. Srivastava MD, Thomas A, Srivastava BI, Check JH: **Expression and modulation of progesterone induced blocking factor (PIBF) and innate immune factors in human leukemia cell lines by progesterone and mifepristone.** *Leuk Lymphoma* 2007, **48**(8):1610-1617.

47. Raghupathy R, Al-Mutawa E, Al-Azemi M, Makhseed M, Azizieh F, Szekeres-Bartho J: **Progesterone-induced blocking factor (PIBF) modulates cytokine production by lymphocytes from women with recurrent miscarriage or preterm delivery.** *J Reprod Immunol* 2009, **80**(1-2):91-99.
48. Baughman G, Wiederrecht GJ, Chang F, Martin MM, Bourgeois S: **Tissue distribution and abundance of human FKBP51, and FK506-binding protein that can mediate calcineurin inhibition.** *Biochem Biophys Res Commun* 1997, **232**(2):437-443.
49. Vermeer H, Hendriks-Stegeman BI, van der Burg B, van Buul-Offers SC, Jansen M: **Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression: a potential marker for glucocorticoid sensitivity, potency, and bioavailability.** *J Clin Endocrinol Metab* 2003, **88**(1):277-284.
50. Gemou-Engesaeth V, Fagerhol MK, Toda M, Hamid Q, Halvorsen S, Groegaard JB, Corrigan CJ: **Expression of activation markers and cytokine mRNA by peripheral blood CD4 and CD8 T cells in atopic and nonatopic childhood asthma: effect of inhaled glucocorticoid therapy.** *Pediatrics* 2002, **109**(2):E24.
51. Roberts G: **Immunotherapy, asthma and community allergic reactions to food.** *Clin Exp Allergy* 2016, **46**(6):780-781.
52. Souffriau J, Eggermont M, Van Ryckeghem S, Van Looveren K, Van Wyngene L, Van Hamme E, Vuylsteke M, Beyaert R, De Bosscher K, Libert C: **A screening assay for Selective Dimerizing Glucocorticoid Receptor Agonists and Modulators (SEDIGRAM) that are effective against acute inflammation.** *Sci Rep* 2018, **8**(1):12894.
53. Spenerova M, Dzubak P, Srovnal J, Radova L, Burianova R, Konecny P, Salkova S, Novak Z, Pospisilova D, Stary J *et al.*: **Combination of prednisolone and low dosed dexamethasone exhibits greater in vitro antileukemic activity than equiactive dose of prednisolone and overcomes prednisolone drug resistance in acute childhood lymphoblastic leukemia.** *Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub* 2014, **158**(3):422-427.
54. Heidari N, Miller AV, Hicks MA, Marking CB, Harada H: **Glucocorticoid-mediated BIM induction and apoptosis are regulated by Runx2 and c-Jun in leukemia cells.** *Cell Death Dis* 2012, **3**:e349.
55. Joshi T, Johnson M, Newton R, Giembycz M: **An analysis of glucocorticoid receptor-mediated gene expression in BEAS-2B human airway epithelial cells identifies distinct, ligand-directed, transcription profiles with implications for asthma therapeutics.** *Br J Pharmacol* 2015, **172**(5):1360-1378.
56. Demirca BP, Cagan H, Kiykim A, Arig U, Arpa M, Tulunay A, Ozen A, Karakoc-Aydiner E, Baris S, Barlan IB: **Nebulized fluticasone propionate, a viable alternative to systemic route in the management of childhood moderate asthma attack: A double-blind, double-dummy study.** *Respir Med* 2015, **109**(9):1120-1125.
57. Castro M, Bloch SR, Jenkerson MV, DeMartino S, Hamilos DL, Cochran RB, Zhang XE, Wang H, Bradley JP, Schechtman KB *et al.*: **Asthma exacerbations after glucocorticoid withdrawal reflects T cell recruitment to the airway.** *Am J Respir Crit Care Med* 2004, **169**(7):842-849.

58. Belda J, Parameswaran K, Lemiere C, Kamada D, O'Byrne PM, Hargreave FE: **Predictors of loss of asthma control induced by corticosteroid withdrawal.** *Can Respir J* 2006, **13**(3):129-133.
59. Troy NM, Hollams EM, Holt PG, Bosco A: **Differential gene network analysis for the identification of asthma-associated therapeutic targets in allergen-specific T-helper memory responses.** *BMC Med Genomics* 2016, **9**:9.
60. Volkmann N, Marassi FM, Newmeyer DD, Hanein D: **The rheostat in the membrane: BCL-2 family proteins and apoptosis.** *Cell Death Differ* 2014, **21**(2):206-215.
61. Cang S, Iragavarapu C, Savooji J, Song Y, Liu D: **ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.** *J Hematol Oncol* 2015, **8**:129.
62. Tian BP, Xia LX, Bao ZQ, Zhang H, Xu ZW, Mao YY, Cao C, Che LQ, Liu JK, Li W *et al*: **Bcl-2 inhibitors reduce steroid-insensitive airway inflammation.** *J Allergy Clin Immunol* 2017, **140**(2):418-430.
63. Huang T, Hazen M, Shang Y, Zhou M, Wu X, Yan D, Lin Z, Solon M, Luis E, Ngu H *et al*: **Depletion of major pathogenic cells in asthma by targeting CRTh2.** *JCI Insight* 2016, **1**(7):e86689.
64. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, Wang L, Kirkesseli S, Rocklin R, Bock B *et al*: **Dupilumab in persistent asthma with elevated eosinophil levels.** *N Engl J Med* 2013, **368**(26):2455-2466.
65. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, FitzGerald JM, Boedigheimer M, Davis BE, Dias C *et al*: **Effects of an anti-TSLP antibody on allergen-induced asthmatic responses.** *N Engl J Med* 2014, **370**(22):2102-2110.
66. Guo W, Li P, Zhao G, Fan H, Hu Y, Hou Y: **Glucocorticoid receptor mediates the effect of progesterone on uterine natural killer cells.** *Am J Reprod Immunol* 2012, **67**(6):463-473.
67. McMurray RW, Wilson JG, Bigler L, Xiang L, Lagoo A: **Progesterone inhibits glucocorticoid-induced murine thymocyte apoptosis.** *Int J Immunopharmacol* 2000, **22**(11):955-965.
68. Volmer T, Effenberger T, Trautner C, Buhl R: **Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature.** *Eur Respir J* 2018, **52**(4).
69. Prazma CM, Wenzel S, Barnes N, Douglass JA, Hartley BF, Ortega H: **Characterisation of an OCS-dependent severe asthma population treated with mepolizumab.** *Thorax* 2014, **69**(12):1141-1142.
70. Salter M, Biggadike K, Matthews JL, West MR, Haase MV, Farrow SN, Uings IJ, Gray DW: **Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease.** *Am J Physiol Lung Cell Mol Physiol* 2007, **293**(3):L660-667.

Table

Table 1 RNA-sequencing of Th2 cells

	RNA Counts		<i>P</i>
	Vehicle	0.1 μ M Dex	
IL-1A	50.1 \pm 17.06	34.3 \pm 9.23	NS
IL-12A	14.3 \pm 1.48	11.7 \pm 3.01	NS
IL-15	12.9 \pm 4.81	8.8 \pm 1.53	NS
CD4	531.9 \pm 68.93	601.1 \pm 86.82	NS
IFNg	225.2 \pm 32.86	79.8 \pm 8.89	< 0.001
IL-23A	71.2 \pm 13.80	95.6 \pm 9.36	0.044
IL-24	5.4 \pm 1.16	12.5 \pm 4.63	0.029
PGR	ND	ND	NS
PIBF1	243.5 \pm 9.78	288.8 \pm 27.17	NS

Abbreviations: Dex, dexamethasone; IL, interleukin; PGR, progesterone receptor; NS, not significant; ND, not detected; PIBF1, progesterone immunomodulatory binding factor 1

Supplemental File Legends

Supplemental Figure S1. Representative flow cytometry of primary Th2 cells differentiated from human CD4⁺ T cells. Gating strategy used to determine percentage of cells positive for IL-4 or IL-13 (vs isotype controls) and to demonstrate a polarized type 2 cytokine profile (IL-13 vs IFNg).

Supplemental Figure S2. The CCRF-CEM cell line exhibits a Th2 phenotype The CD4⁺ T lymphoblastic leukemia cell line CCRF-CEM are enriched in mRNA levels of CRTh2 and GATA3, markers of the Th2 cell phenotype, compared to Jurkat, another CD4⁺ T cell line (n=3, A). Type 2 (IL-13) and type 1 (IFNg) cytokine levels in CCRF-CEM and Jurkat cells following stimulation (24 hours) with PMA (20ng/ml) and ionomycin (1mM) (B). Data represent mean and standard error. **p* < 0.05 determined by one-way ANOVA

Supplemental Figure S3. Gating strategy used to determine the percentage of Annexin V⁺ and 7-AAD⁻ positive cells.

Figures




Figure 1

A comparison of prednisolone- and dexamethasone-mediated reduction of type-2 cytokine mRNA levels in primary Th2 cells. Fold differences in mRNA level from corticosteroid (CS) treated cells compared to vehicle are provided (n=3). Quantification of IL-13 mRNA following steroid treatment (A). Comparison of CS ability to suppress IL-13 (B). The half maximal inhibitory concentration (IC₅₀) for prednisolone and dexamethasone required to suppress IL-13 mRNA expression (C). Quantification of IL-5 mRNA following

CS treatment (D). Comparison of the ability of either CS to suppress IL-5 (E). A comparison of the IC50 values for prednisolone and dexamethasone required to suppress IL-5 mRNA expression (F). Cell counts following culture in vehicle or increasing concentration of prednisolone or dexamethasone (G). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone.* $p < 0.05$ determined by one-way (A, D & G) or two-way (B & E) RM ANOVA or t-test (C & F).




Figure 2

A comparison of prednisolone- and dexamethasone-induced apoptosis in a Th2 cell line (CCRF-CEM). Data are expressed as percentage of 7AAD+ cells (A) identifying dead cells. The half maximal dose (EC50) for prednisolone and dexamethasone required to induce necrosis of cells (B). Percentage of Annexin V+ 7AAD- cells, identifying apoptotic cells (C). A comparison of the EC50 values for prednisolone and dexamethasone required to reach 50% maximal induction of apoptosis in cells (D; n=11). Percentage of Annexin V+ 7AAD- primary Th2 cells following treatment with dexamethasone, exhibiting a similar plateau effect as CCRF-CEM at 0.5 μ M dexamethasone (E; n=3). Comparison of CS-induced apoptosis in CCRF-CEM as fold-difference over vehicle (F). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone. *p < 0.05 determined by two-way (A & C), t-test (B & E) or one-way RM ANOVA (G).




Figure 3

Corticosteroid-induced cell death is dampened by the female sex hormone progesterone. Dexamethasone-induced cell death (A, % 7AAD+) and apoptosis (B, % Annexin V+ 7AAD-) of a Th2 cell line (CCRF-CEM) in the presence or absence of progesterone (2 μM , n=5). Head-to-head comparison of apoptosis following treatment with prednisolone (C) or dexamethasone (D) with or without progesterone (n=4). The half maximal response (EC₅₀) for dexamethasone and prednisolone in the presence of

progesterone (E). Influence of progesterone on the maximal response of prednisolone- or dexamethasone-induced apoptosis (F). Efficacy of prednisolone vs dexamethasone to induce apoptosis in the presence of prednisolone (G). Data represent mean and standard error. Pred, prednisolone; Dex, dexamethasone; Prog, progesterone; Pre, pretreatment. * $p < 0.05$ determined by one-way (A-E) or two-way (F & G) RM ANOVA.




Figure 4

Expression of the nuclear progesterone receptor (PGR) is undetectable in a Th2 cell line (CCRF-CEM) and primary Th2 cells, but present in a breast adenocarcinoma cell line (MCF-7) used as a positive control

(n=3; A). Effect of progesterone with or without dexamethasone on expression of PIBF1 (n=3, B). Progesterone reduced the dexamethasone-mediated increase in FKPB5 mRNA level, but had no effect when applied alone (n=5, C). Data represent mean and standard error. *p < 0.05 determined by one-way ANOVA

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [suppfig1.png](#)
- [suppfig2.png](#)
- [suppfig3.png](#)